guest ::
| Home > Publications database > Regional grey-matter A1 adenosine receptor expression in patients with early-stage Multiple Sclerosis: An in vivo PET study |
| Home > Publications database > Regional grey-matter A1 adenosine receptor expression in patients with early-stage Multiple Sclerosis: An in vivo PET study |
| Conference Presentation (After Call) | FZJ-2024-04023 |
; ; ; ; ; ; ; ;
2023
This record in other databases:
Please use a persistent id in citations: doi:10.1055/s-0043-1766271
Abstract: Ziel/Aim Various studies indicate that cerebral adenosine modulates autoimmuneand inflammatory conditions. In line, experiments in rodents as well aspost-mortem investigations in humans suggested that adenosine and the A1adenosine receptor (A1AR), which is the most abundant adenosine receptor inthe brain, plays an important role in the pathogenesis of multiple sclerosis (MS).In this study, we investigated the in vivo cerebral A1AR availability in earlystageMS patients.Methodik/Methods Cerebral A1AR availability was investigated in vivo via PETwith the A1AR-specific radiotracer F-18-CPFPX in 15 early-stage MS patientsbeing free of disease-specific medication, as well as in 14 age- and sex-matchedhealthy controls. Regional A1AR availability was determined quantitatively forgrey matter volumes of interest (VOI) by equilibrium analysis and comparedbetween patients and controls, between subgroups of patients, and betweenpairs of VOIs located on both hemispheres of the brain.Ergebnisse/Results There were no global differences in A1AR availability ingrey matter regions of MS patients in comparison to healthy controls nor withinclinical MS subtypes. However, single brain regions exhibited significant differencesin A1AR availability between both hemispheres (precentral gyrus, postcentralgyrus, cerebellum, presubgenual frontal cortex, subgenual frontalcortex, posterior part of superior temporal gyrus, anterior part of superiortemporal gyrus) in MS patients.Schlussfolgerungen/Conclusions Summarizing, this study shows that thereare no global alterations of A1AR availability in cerebral grey matter at earlystages of MS pathology. However, we observed patient-specific interhemisphericdeviations of A1AR grey matter availability that require further investigation.
|
The record appears in these collections: |